Abstract
Neuropilin-2 (NRP2) is a cell surface receptor that has been identified as the binding partner for efzofitimod, a novel immunomodulatory molecule in development as a potential treatment of pulmonary sarcoidosis and other interstitial lung diseases (ILDs). To date, the availability of reagents for immunohistochemical (IHC) detection of NRP2 protein in patient tissue samples has been less than ideal, as commercially available anti-NRP2 antibodies tend to display high non-specific staining. We aimed to generate and validate a specific and sensitive anti-NRP2 antibody for use in IHC staining of patient tissue samples.
We have generated a panel of anti-human NRP2 monoclonal antibodies for a variety of research uses. A promising candidate for IHC was identified by Western blotting and validated by staining cells known to be positive and negative for NRP2 and by specific blocking with NRP2 peptides.
This novel antibody against human NRP2 was validated for use in IHC and was shown to be highly specific for NRP2, binding to all major splice variants while displaying no background staining and no cross-reactivity with neuropilin-1. Using this antibody, we demonstrated a high level of NRP2 protein expression in granulomas of sarcoidosis patient lung and skin biopsy samples.
This antibody provides a specific and sensitive IHC detection method for NRP2 in patient tissue samples and could be a useful clinical tool (e.g. for facilitating patient selection or as a predictive biomarker) in sarcoidosis, other ILDs, oncology and other indications in which NRP2 plays a role.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4531.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
